Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer

Tohoku Journal of Experimental Medicine

Volumn 236, Issue 4, 2015, Pages 297-304

  Hong, Xuan ^a   Cui, Baohong ^a   Wang, Meng ^a   Yang, Zhaoyang ^a   Wang, Li ^a   Xu, Qingyong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Hematological indices; Inflammation; Prognostic factors; Small cell lung cancer; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SMALL CELL LUNG CANCER; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UNIVARIATE ANALYSIS; VERY ELDERLY; AGE; BLOOD; IMMUNOLOGY; LEUKOCYTE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SMALL CELL LUNG CARCINOMA; SMOKING; SURVIVAL;

AGE FACTORS; HUMANS; L-LACTATE DEHYDROGENASE; LEUKOCYTES; NEUTROPHILS; PLATELET COUNT; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SMALL CELL LUNG CARCINOMA; SMOKING; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84940050469     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.236.297     Document Type: Article

References (40)

1. Albain, K.S., Crowley, J.J., LeBlanc, M. & Livingston, R.B. (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J. Clin. Oncol., 8, 1563-1574.
2. Albain, K.S., Crowley, J.J., LeBlanc, M. & Livingston, R.B. (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Groupexperience. J. Clin. Oncol., 9, 1618-1626.
3. Balkwill, F. & Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
4. Bremnes, R.M., Sundstrom, S., Aasebø, U., Kaasa, S., Hatlevoll, R. & Aamdal, S.; Norweigian Lung Cancer Study Group (2003) The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 39, 303-313.
5. Brigham, B.A., Bunn, P.A. Jr., Minna, J.D., Cohen, M.H., Ihde, D.C. & Shackney, S.E. (1978) Growth rates of small cell bronchogenic carcinomas. Cancer, 42, 2880-2886.
6. Cetin, B., Afsar, B., Deger, S.M., Gonul, I.I., Gumusay, O., Ozet, A., Benekli, M., Coskun, U. & Buyukberber, S. (2014) Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. Int. Urol. Nephrol., 46, 1081-1087.
7. Dellapasqua, S., Bagnardi, V., Bertolini, F., Sandri, M.T., Pastrello, D., Cancello, G., Montagna, E., Balduzzi, A., Mancuso, P., Luini, A., Goldhirsch, A. & Colleoni, M. (2012) Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast, 21, 309-313.
8. Dowell, J.E. (2010) Small cell lung cancer: are we making progress? Am. J. Med. Sci., 339, 68-76.
9. Evans, W.K., Shepherd, F.A., Feld, R., Osoba, D., Dang, P. & Deboer, G. (1985) VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J. Clin. Oncol., 3, 1471-1477.
10. Foster, N.R., Mandrekar, S.J., Schild, S.E., Nelson, G.D., Rowland, K.M. Jr., Deming, R.L., Kozelsky, T.F., Marks, R.S., Jett, J.R. & Adjei, A.A. (2009) Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer, 115, 2721-2731.
11. Han, X., Stevens, J. & Bradshaw, P.T. (2013) Body mass index, weight change, and survival in non-Hodgkin lymphoma patients in Connecticut women. Nutr. Cancer, 65, 43-50.
12. Hermes, A., Gatzemeier, U., Waschki, B. & Reck, M. (2010) Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer: a retrospective single institution analysis. Respir. Med., 104, 1937-1942.
13. Hu, B., Yang, X.R., Xu, Y., Sun, Y.F., Sun, C., Guo, W., Zhang, X., Wang, W.M., Qiu, S.J., Zhou, J. & Fan, J. (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellularcarcinoma. Clin. Cancer Res., 20, 6212-6222.
14. Kang, M.H., Go, S.I., Song, H.N., Lee, A., Kim, S.H., Kang, J.H., Jeong, B.K., Kang, K.M., Ling, H. & Lee, G.W. (2014) The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br. J. Cancer, 111, 452-460.
15. Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Fushiya, N., Koike, K., Nishino, H. & Tajiri, H. (2012) Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br. J. Cancer, 107, 988-993.
16. Lee, S., Oh, S.Y., Kim, S.H., Lee, J.H., Kim, M.C., Kim, K.H. & Kim, H.J. (2013) Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer, 22, 350.
17. Liu, X., Meng, Q.H., Ye, Y., Hildebrandt, M., Gu, J. & Wu, X. (2015) Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic breast cancer. Carcinogenesis, 36, 243-248.
18. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. (2008) Cancer-related inflammation. Nature, 454, 436-444.
19. McMillan, D.C. (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care, 12, 223-226.
20. Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 361, 947-957.
21. National Cancer Institute at National Institutes of Health (2015) Small cell lung cancer Treatment for health professionals. http://www.cancer.gov/cancertopics/pdq/treatment/small-celllung/healthprofessional/page1 [Accessed: April 30, 2015].
22. Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., Yamamoto, S. & Saijo, N.; Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med., 346, 85-91.
23. Pai, P.C., Chuang, C.C., Tseng, C.K., Tsang, N.M., Chang, K.P., Yen, T.C., Liao, C.T., Hong, J.H. & Chang, J.T. (2012) Impact of pretreatment body mass index on patients with head-andneck cancer treated with radiation. Int. J. Radiat. Oncol. Biol. Phys., 83, e93-e100.
24. Paramanathan, A., Saxena, A. & Morris, D.L. (2014) A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg. Oncol., 23, 31-39.
25. Philipp, A.B., Nagel, D., Stieber, P., Lamerz, R., Thalhammer, I., Herbst, A. & Kolligs, F.T. (2014) Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer, 14, 245.
26. Pinato, D.J., North, B.V. & Sharma, R. (2012) A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br. J. Cancer, 106, 1439-1445.
27. Pinato, D.J., Stavraka, C., Flynn, M.J., Forster, M.D., O’Cathail, S.M., Seckl, M.J., Kristeleit, R.S., Olmos, D., Turnbull, S.J. & Blagden, S.P. (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One, 9, e83279.
28. Proctor, M.J., Morrison, D.S., Talwar, D., Balmer, S.M., Fletcher, C.D., O’Reilly, D.S., Foulis, A.K., Horgan, P.G. & McMillan, D.C. (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur. J. Cancer, 47, 2633-2641.
29. Qu, X., Zhang, T., Ma, H., Sui, P. & Du, J. (2014) Lower mean corpuscular hemoglobin concentration is associated with unfavorable prognosis of resected lung cancer. Future Oncol., 10, 2149-2159.
30. Roth, B.J., Johnson, D.H., Einhorn, L.H., Schacter, L.P., Cherng, N.C., Cohen, H.J., Crawford, J., Randolph, J.A., Goodlow, J.L., Broun, G.O., Omura, G.A. & Greco, F.A. (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol., 10, 282-291.
31. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R. & Johnson, D.H. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N. Engl. J. Med., 355, 2542-2550.
32. Socinski, M.A., Weissman, C., Hart, L.L., Beck, J.T., Choksi, J.K., Hanson, J.P., Prager, D., Monberg, M.J., Ye, Z. & Obasaju, C.K. (2006) Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J. Clin. Oncol., 24, 4840-4847.
33. Sun, J.M., Choi, Y.L., Ji, J.H., Ahn, J.S., Kim, K.M., Han, J., Ahn, M.J. & Park, K. (2015) Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann. Oncol., 26, 161-166.
34. Takada, M., Fukuoka, M., Kawahara, M., Sugiura, T., Yokoyama, A., Yokota, S., Nishiwaki, Y., Watanabe, K., Noda, K., Tamura, T., Fukuda, H. & Saijo, N. (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol., 20, 3054-3060.
35. Tas, F., Aydiner, A., Demir, C. & Topuz, E. (2001) Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am. J. Clin. Oncol., 24, 376-378.
36. Ulas, A., Turkoz, F.P., Silay, K., Tokluoglu, S., Avci, N., Oksuzoglu, B. & Alkis, N. (2014) A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One, 9, e114471.
37. Wang, X., Jiang, R. & Li, K. (2014) Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem. Biophys., 69, 633-640.
38. Weide, B., Richter, S., Büttner, P., Leiter, U., Forschner, A., Bauer, J., Held, L., Eigentler, T.K., Meier, F. & Garbe, C. (2013) Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One, 8, e81624.
39. Zakowski, M.F. (2003) Pathology of small cell carcinoma of the lung. Semin. Oncol., 30, 3-8.
40. Zhou, T., Hong, S., Hu, Z., Hou, X., Huang, Y., Zhao, H., Liang, W., Zhao, Y., Fang, W., Wu, X., Qin, T. & Zhang, L. (2015) A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol., 36, 337-343.